Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Royal Melbourne Hospital, Australia | UNKNOWN |
Not provided
Not provided
Not provided
This is a pilot, multi-centre, randomised clinical trial evaluating the safety and feasibility of a home-based oral food challenge in adults with low-risk food allergy labels. Eligible participants are aged 18 years or older and have a self-reported food allergy with negative skin prick testing to the implicated food. Participants will be randomised to either a home-based or standard in-clinic food challenge. The primary aim is to determine the safety of home challenges, measured by the rate of immune-mediated adverse events. Secondary aims include feasibility of recruitment and delivery, protocol adherence, quality of life, and food reintroduction outcomes.
Food allergies are highly prevalent and contribute to significant patient anxiety and healthcare utilisation. Many individuals carry food allergy labels without confirmation through diagnostic food challenge, resulting in unnecessary food avoidance. In-clinic food challenges are the current standard for confirming tolerance but are resource-intensive and often delayed. This study evaluates whether selected low-risk adults can safely complete a structured oral food challenge at home.
This is a pilot, multi-centre, randomised controlled trial conducted at two tertiary allergy centres in Victoria, Australia (Austin Health and Royal Melbourne Hospital). Adults referred with a reported food allergy will undergo clinical assessment and skin prick testing. Those with negative skin testing (<3mm wheal) to the implicated food and meeting other eligibility criteria will be randomised 1:1 to either:
The primary outcome is the proportion of participants experiencing an immune-mediated adverse event during food challenge. Secondary outcomes include feasibility metrics (eligibility, recruitment, delivery), non-immune mediated adverse events, protocol adherence, quality of life (measured by FAQLQ-12), time to challenge, and real-world food reintroduction.
The study will enrol 120 participants (60 per arm). Outcomes will inform the design of a future non-inferiority trial and may support integration of home challenges into routine practice for selected patients.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| In-Clinic Food Challenge (Control Arm) | Other | Participants randomised to the control arm will undergo a standard in-clinic oral food challenge conducted under direct medical supervision. The protocol used is derived from the PRACTALL consensus and ASCIA position statements and involves administration of increasing doses of the implicated food at 20-30 minute intervals over a 2-3 hour period. Observation continues for 1-2 hours post final dose. The challenge is performed in a hospital outpatient clinic equipped for anaphylaxis management. The food challenged is selected by the participant from their eligible food allergy labels. |
|
| Home-Based Food Challenge (Intervention Arm) | Experimental | Participants randomised to the intervention arm will undertake a structured home-based oral food challenge over five consecutive days. This begins with an initial supervised dose administered in clinic under medical observation (60-minute monitoring period). Participants will then self-administer increasing doses of the implicated food at home each subsequent day using a standardised protocol adapted from PRACTALL and ASCIA guidelines. Dose intervals are 24 hours to reduce risk of cumulative reactions. Participants are provided with written instructions, emergency action plans, and have daily phone follow-up with allergy nursing staff during the challenge. The challenge food is selected by the participant from their eligible food allergy labels. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Home-Based Food Challenge | Diagnostic Test | Participants randomised to the intervention arm will undertake a structured home-based oral food challenge over five consecutive days. This begins with an initial supervised dose administered in clinic under medical observation (60-minute monitoring period). Participants will then self-administer increasing doses of the implicated food at home each subsequent day using a standardised protocol adapted from PRACTALL and ASCIA guidelines. Dose intervals are 24 hours to reduce risk of cumulative reactions. Participants are provided with written instructions, emergency action plans, and have daily phone follow-up with allergy nursing staff during the challenge. The challenge food is selected by the participant from their eligible food allergy labels. |
| Measure | Description | Time Frame |
|---|---|---|
| Proportion of participants experiencing immune-mediated adverse events during food challenge | Immune-mediated adverse events are defined as clinical symptoms consistent with IgE-mediated food allergy occurring during the food challenge, including but not limited to: urticaria, angioedema, vomiting, diarrhoea, or respiratory compromise (e.g., wheezing, cough, stridor). Events will be recorded according to a standardised adverse event form. For home challenges, participants will self-report symptoms daily and receive follow-up via nursing staff. In-clinic events will be recorded by supervising clinicians. | During the food challenge period (Days 1-5 post-randomisation) |
| Measure | Description | Time Frame |
|---|---|---|
| Proportion of screened patients who are eligible for randomisation (Eligibility-to-screened ratio) | Feasibility metric defined as the proportion of patients referred to outpatient allergy clinic who meet the trial eligibility criteria (including negative skin prick testing to the implicated food and absence of exclusion criteria). | Baseline visit |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Austin Health | Recruiting | Melbourne | Victoria | Australia |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 41651530 | Derived | Godsell J, Vogrin S, Chan S, Henri M, Ng I, Andrews E, Spriggs K, Perrett KP, Trubiano J. FoodCHOMP (Food Challenge-at HOme or in Medical Practice): a pilot multicentre randomised controlled trial evaluating home versus clinic-based food allergy challenges in low-risk adults-study protocol. BMJ Open. 2026 Feb 6;16(2):e114483. doi: 10.1136/bmjopen-2025-114483. |
Not provided
Not provided
There is no plan to share IPD with other researchers
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D005512 | Food Hypersensitivity |
| ID | Term |
|---|---|
| D006969 | Hypersensitivity, Immediate |
| D006967 | Hypersensitivity |
| D007154 | Immune System Diseases |
Not provided
Not provided
This study uses a parallel assignment model. Participants who meet eligibility criteria are randomly assigned in a 1:1 ratio to one of two arms: a home-based food challenge group (intervention) or a standard in-clinic food challenge group (control). Each participant undergoes only one of the two interventions, and there is no crossover between arms. Randomisation is stratified by site and gender and conducted via REDCap using a permuted block design.
Not provided
Not provided
Not provided
Not provided
|
| In-Clinic Food Challenge | Diagnostic Test | Standard of care - Participants randomised to the control arm will undergo a standard in-clinic oral food challenge conducted under direct medical supervision. The protocol used is derived from the PRACTALL consensus and ASCIA position statements and involves administration of increasing doses of the implicated food at 20-30 minute intervals over a 2-3 hour period. Observation continues for 1-2 hours post final dose. The challenge is performed in a hospital outpatient clinic equipped for anaphylaxis management. The food challenged is selected by the participant from their eligible food allergy labels. |
|
| Proportion of eligible patients who consent to participate (Recruitment-to-eligibility ratio) | Feasibility of recruitment measured as the proportion of eligible patients who provide written informed consent to participate in the trial. | At consent discussion (baseline visit) |
| Proportion of randomised participants who receive the allocated intervention (Intervention-to-recruitment ratio) | Defined as the proportion of randomised participants who complete their allocated food challenge (home or in-clinic) in accordance with protocol. | Day 1 to Day 5 (intervention delivery period) |
| Proportion of participants experiencing non-immune mediated adverse events | Non-immune mediated events include those not consistent with IgE-mediated allergy and not meeting serious adverse event criteria. Examples: taste aversion, food refusal, procedural anxiety. Events will be recorded via self-report or in-clinic observation. | Day 1 to Day 5 (challenge period) |
| Proportion of participants with severe adverse reactions (anaphylaxis or death) | Serious adverse events are defined per ICH-GCP and include anaphylaxis (as per ASCIA criteria) or death. | Day 1 to Day 5 (challenge period) |
| Difference in proportion of participants tolerant to challenge food | Defined as the proportion of participants in each arm who successfully consume the full challenge dose without meeting stopping criteria or experiencing adverse events. Tolerance is determined according to protocol-defined thresholds. | At completion of challenge (Day 5) |
| Change in Food Allergy Quality of Life (FAQLQ-12) score from baseline | Measured using the FAQLQ-12, a validated 12-item quality of life tool for adults with food allergy. Change in score will be assessed as a continuous variable. | Baseline and 6 months post-randomisation |
| Proportion of participants consuming the challenge food post-trial | Defined as the proportion of participants who report active inclusion of the challenge food in their diet at least once per week following a successful challenge. | At 6-month follow-up |
| Time from clinic referral to challenge completion | Measured in days to assess whether home-based challenge reduces diagnostic delay compared to in-clinic challenge. Data collected through clinic administrative records. | From the date of referral for food challenge to date of challenge completion or withdrawal from the study assessed up to 60 months. |
| Royal Melbourne Hospital | Recruiting | Melbourne | Victoria | Australia |
|